180 participants
Phase 1 Study to Assess Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of ARR-002 in Advanced or Metastatic Ovarian or Endometrial Cancer.
- Study Type:
- INTERVENTIONAL
- Last Updated:
- 2026-08-10
- Start Date:
- 2026-07-23
- Completion:
- 2027-08-31
Conditions
- Ovarian Cancer
- Endometrial Cancer
- Platinum-resistant Ovarian Cancer (PROC)
- Metastatic Ovarian Cancer
- Metastatic Endometrial Cancer
Interventions
- DRUG
No Results Yet